BR0208652A - Composição parenteral reconstituìvel contendo um inibidor de cox-2 - Google Patents

Composição parenteral reconstituìvel contendo um inibidor de cox-2

Info

Publication number
BR0208652A
BR0208652A BR0208652-2A BR0208652A BR0208652A BR 0208652 A BR0208652 A BR 0208652A BR 0208652 A BR0208652 A BR 0208652A BR 0208652 A BR0208652 A BR 0208652A
Authority
BR
Brazil
Prior art keywords
composition
cox
weight
inhibitor
composition containing
Prior art date
Application number
BR0208652-2A
Other languages
English (en)
Other versions
BR0208652B1 (pt
BRPI0208652B8 (pt
Inventor
Tugrul T Kararli
Sandeep Nema
Aziz Karim
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23075770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0208652(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0208652A publication Critical patent/BR0208652A/pt
Publication of BR0208652B1 publication Critical patent/BR0208652B1/pt
Publication of BRPI0208652B8 publication Critical patent/BRPI0208652B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSIçãO PARENTERAL RECONSTITUìVEL CONTENDO UM INIBIDOR DE COX-2". Uma composição farmacêutica compreende, em forma de pó, (a) pelo menos um agente terapêutico solúvel em água selecionado de drogas e pró-drogas inibidoras de COX-2 seletivas e sais das mesmas, por exemplo sódio de parecoxib, em uma constituição de quantidade total terapeuticamente eficaz em cerca de 30% a cerca de 90% em peso, (b) um agente de tamponamento parenteralmente aceitável em uma quantidade de cerca de 5% a cerca de 60% em peso, e opcionalmente (c) outros ingredientes excipientes parenteralmente aceitáveis em uma quantidade total não maior do que cerca de 10% em peso, da composição. A composição é reconstituível em um líquido solvente parenteralmente aceitável, para formar uma solução injetável. Um processo de liofilização é fornecido para a preparação de uma tal composição.
BRPI0208652A 2001-04-03 2002-04-02 composição farmacêutica parenteral reconstituível contendo parecoxib sódico, solução injetável e frasco selado compreendendo a mesma BRPI0208652B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28105801P 2001-04-03 2001-04-03
PCT/US2002/010252 WO2002080912A1 (en) 2001-04-03 2002-04-02 Reconstitutable parenteral composition containing a cox-2 inhibitor

Publications (3)

Publication Number Publication Date
BR0208652A true BR0208652A (pt) 2004-03-02
BR0208652B1 BR0208652B1 (pt) 2017-10-31
BRPI0208652B8 BRPI0208652B8 (pt) 2021-05-25

Family

ID=23075770

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0208652A BRPI0208652B8 (pt) 2001-04-03 2002-04-02 composição farmacêutica parenteral reconstituível contendo parecoxib sódico, solução injetável e frasco selado compreendendo a mesma

Country Status (46)

Country Link
US (1) US7695736B2 (pt)
EP (1) EP1372645B1 (pt)
JP (1) JP4511792B2 (pt)
KR (1) KR100980685B1 (pt)
CN (3) CN107213121A (pt)
AP (1) AP1776A (pt)
AR (1) AR033688A1 (pt)
AT (1) ATE310516T1 (pt)
AU (1) AU2002256031B2 (pt)
BG (1) BG66367B1 (pt)
BR (1) BRPI0208652B8 (pt)
CA (1) CA2442906C (pt)
CZ (1) CZ299623B6 (pt)
DE (1) DE60207535T2 (pt)
DK (1) DK1372645T3 (pt)
EA (1) EA006554B1 (pt)
EC (1) ECSP034789A (pt)
EG (1) EG24345A (pt)
ES (1) ES2252448T3 (pt)
GE (1) GEP20063775B (pt)
GT (1) GT200200065A (pt)
HK (2) HK1243338A1 (pt)
HR (1) HRP20030793B1 (pt)
HU (1) HU229264B1 (pt)
IL (2) IL158209A0 (pt)
IS (1) IS2408B (pt)
JO (1) JO2337B1 (pt)
MA (1) MA27008A1 (pt)
ME (1) MEP56908A (pt)
MX (1) MXPA03009013A (pt)
MY (1) MY137736A (pt)
NO (1) NO333381B1 (pt)
NZ (1) NZ528547A (pt)
OA (1) OA12498A (pt)
PA (1) PA8542701A1 (pt)
PE (1) PE20021017A1 (pt)
PL (1) PL205658B1 (pt)
RS (1) RS50430B (pt)
SI (1) SI1372645T1 (pt)
SK (1) SK287754B6 (pt)
SV (1) SV2002000969A (pt)
TN (2) TNSN02039A1 (pt)
TW (1) TWI314867B (pt)
UA (1) UA77173C2 (pt)
WO (1) WO2002080912A1 (pt)
ZA (1) ZA200307630B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2259197C2 (ru) * 2000-11-02 2005-08-27 Кромасьютикал Эдванст Текнолоджиз, Инк. Способ получения очищенного гематинового комплекса железо-сахарид и полученный продукт
US6929954B2 (en) * 2000-11-02 2005-08-16 Chromaceutical Advanced Technologies, Inc. Method for producing purified hematinic iron-saccharidic complex and product produced
ATE383156T1 (de) * 2001-11-13 2008-01-15 Pharmacia Corp Oral verabreichbare zusammensetzung enthaltend parecoxib
CA2478500A1 (en) * 2002-03-15 2003-09-25 Pharmacia Corporation Crystalline parecoxib sodium
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
DE10327674A1 (de) * 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
KR20080016689A (ko) * 2005-05-27 2008-02-21 파나세아 바이오테크 리미티드 약물주사가 가능한 새로운 형태의 조성물 및 이러한조성물을 위한 조제방법
CN101442985A (zh) * 2006-05-09 2009-05-27 阿斯利康(瑞典)有限公司 在其最终容器中被电离辐射灭菌了的包含质子泵抑制剂的肠胃外制剂
JP5466006B2 (ja) * 2006-09-03 2014-04-09 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚浸透率を有するアセトアミノフェン及び関連化合物の正荷電水溶性プロドラッグ
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US20090143762A1 (en) * 2007-11-29 2009-06-04 Alltranz Inc. Methods and Compositions for Enhancing the Viability Of Microneedle Pores
KR100967490B1 (ko) * 2009-11-21 2010-07-07 곽철호 하수구의 배출 처리 구조
BR112014010542A2 (pt) 2011-11-02 2017-04-18 Halscion Inc métodos e composições para tratamento de ferimento
MX352601B (es) 2011-12-23 2017-11-30 Pioneer Surgical Tech Matriz continua con particulas osteoconductoras dispersadas en ella, método para formarla y método para regenerar hueso con ella.
CN102512383A (zh) * 2011-12-25 2012-06-27 天津市嵩锐医药科技有限公司 供注射用的帕瑞昔布钠药物组合物
CN104771370B (zh) * 2014-01-14 2020-07-24 南京圣和药业股份有限公司 帕瑞昔布钠冻干粉针剂及其制备方法
JP2017505349A (ja) 2014-02-11 2017-02-16 ドクター レディズ ラボラトリーズ リミテッド セレコキシブの非経口組成物
CN105726496B (zh) * 2014-12-12 2019-05-28 湖南科伦药物研究有限公司 一种帕瑞昔布钠冻干粉剂、其制备方法及其粉剂产品
CN105125506A (zh) * 2015-08-18 2015-12-09 上海秀新臣邦医药科技有限公司 一种注射用帕瑞昔布钠及其制备方法
CN105168152B (zh) * 2015-08-27 2018-06-01 上海华源药业（宁夏）沙赛制药有限公司 一种帕瑞昔布钠冻干粉及其制备方法
US10639340B2 (en) 2018-06-18 2020-05-05 Eric Young Method of drying botanicals
US11243028B2 (en) * 2018-12-14 2022-02-08 Fortunata, LLC Systems and methods of cryo-curing
EP3932397A4 (en) 2019-03-01 2022-12-07 Eurofarma Laboratórios S.A. FREEZE-DRIED PHARMACEUTICAL COMPOSITION OF NON-STEROIDAL ANTI-INFLAMMATORY
CN110960493B (zh) * 2019-12-30 2022-03-11 山东罗欣药业集团股份有限公司 一种帕瑞昔布钠冻干制剂及其制备方法
CN113456597B (zh) * 2020-03-30 2023-02-14 石药集团欧意药业有限公司 一种注射用帕瑞昔布钠及其制备方法
CN116421569B (zh) * 2023-06-15 2023-09-05 四川尚锐生物医药有限公司 一种注射用帕瑞昔布钠药物组合物及其制备方法

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434163A (en) 1981-06-01 1984-02-28 Pfizer Inc. Water-soluble benzothiazine dioxide salts
US4797388A (en) * 1984-05-21 1989-01-10 Cetus Corporation Pharmaceutical compositions with galactitol as carrier
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US5036060A (en) * 1988-07-25 1991-07-30 Fujisawa Usa, Inc. Cyclophosphamide
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
CA2243199C (en) 1993-01-15 2005-08-02 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5344991A (en) 1993-10-29 1994-09-06 G.D. Searle & Co. 1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5401765A (en) 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
US5434178A (en) 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5475018A (en) 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation
US5393790A (en) 1994-02-10 1995-02-28 G.D. Searle & Co. Substituted spiro compounds for the treatment of inflammation
AU2424895A (en) 1994-05-04 1995-11-29 G.D. Searle & Co. Substituted spirodienes for the treatment of inflammation
US5418254A (en) 1994-05-04 1995-05-23 G. D. Searle & Co. Substituted cyclopentadienyl compounds for the treatment of inflammation
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
US5486534A (en) 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
EP0772606A1 (en) 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5420343A (en) 1994-08-31 1995-05-30 G. D. Searle & Co. Derivatives of aromatic cyclic alkylethers
US5585504A (en) 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5696143A (en) 1994-09-20 1997-12-09 Talley; John J. Benz G! indazolyl derivatives for the treatment of inflammation
AU688980B2 (en) 1994-10-27 1998-03-19 Merck Frosst Company Stilbene derivatives useful as cyclooxygenase-2 inhibitors
US5739166A (en) 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
JP3181190B2 (ja) 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
AU702591B2 (en) 1994-12-21 1999-02-25 Merck Frosst Canada Ltd. Diaryl-2-(5H)-furanones as cox-2 inhibitors
US5552422A (en) 1995-01-11 1996-09-03 Merck Frosst Canada, Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
CA2211320C (en) 1995-01-31 2007-03-20 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
US5596008A (en) 1995-02-10 1997-01-21 G. D. Searle & Co. 3,4-Diaryl substituted pyridines for the treatment of inflammation
US5686470A (en) 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
JP3802581B2 (ja) 1995-03-01 2006-07-26 富山化学工業株式会社 新規なビフェニル誘導体またはその塩およびそれらを含有する抗炎症剤
TR199701105T1 (xx) 1995-04-04 1998-02-21 Glaxo Group Limited �midazo (1,2-a)piridin t�revleri.
US5691374A (en) 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
RU2251543C2 (ru) 1995-05-25 2005-05-10 Джи.Ди.Сирл энд Ко. Дикетон в качестве промежуточного продукта при получении 3-галоген-1н-пиразолов
US5643933A (en) 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
GB9514518D0 (en) 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
JPH0977664A (ja) 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
US5756529A (en) 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US5981576A (en) 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6057319A (en) 1995-10-30 2000-05-02 Merck Frosst Canada & Co. 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
ES2205167T3 (es) 1996-01-11 2004-05-01 Smithkline Beecham Corporation Nuevos compuestos de imidazol sustituidos.
ZA97175B (en) 1996-01-11 1997-11-04 Smithkline Beecham Corp Novel substituted imidazole compounds.
US6046208A (en) 1996-01-11 2000-04-04 Smithkline Beecham Corporation Substituted imidazole compounds
US5746546A (en) * 1996-01-24 1998-05-05 Stabilizer, Inc. Soil stabilization composition and method
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
GB9607503D0 (en) 1996-04-11 1996-06-12 Merck Frosst Canada Inc Bisaryl cyclobutenes derivatives as cyclooxygenase inhibitors
US5807873A (en) 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
HU225473B1 (en) * 1996-04-12 2006-12-28 Searle & Co Heterocycle substituted n-acyl benzenesulfonamide derivatives, process for their preparation and their use as prodrug for the preparation of pharmaceutical compositions treating inflammation or inflammation-associated disorders
US5922742A (en) 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5883267A (en) 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
US5741798A (en) 1996-06-03 1998-04-21 Boehringer Ingelheim Pharmaceuticals, Inc. 2-benzyl-4-sulfonyl-4H-isoquinolin-1,3-diones and their use as antiinflammatory agents
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
FR2751966B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
FR2751964B1 (fr) 1996-08-01 1998-10-30 Union Pharma Scient Appl Nouveaux derives diarylmethylene carbocycliques, leurs procedes de preparation, et leurs utilisations en therapeutique
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6005000A (en) 1996-08-22 1999-12-21 Oxis International, Inc. 5,5-Disubstituted-3, 4-dihydroxy-2(5H)-furanones and methods of use therefor
FR2753449B1 (fr) 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
US5972950A (en) 1996-10-08 1999-10-26 Laboratories Upsa 1,2-diarylmethylene derivatives, their methods of preparation and their uses in therapeutics
US5681842A (en) 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
US5869524A (en) 1996-11-12 1999-02-09 American Home Products Corporation Indene inhibitors of COX-2
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
DE69727199T2 (de) 1996-12-09 2004-11-18 Pfizer Inc. Benzimidazol-Verbindungen
DK0946507T3 (da) 1996-12-10 2004-01-26 Searle & Co Substituerede pyrrolylforbindelser til behandling af inflammation
US5973191A (en) 1996-12-30 1999-10-26 Vanderbilt University Selective inhibitors of prostaglandin endoperoxide synthase-2
US5929076A (en) 1997-01-10 1999-07-27 Smithkline Beecham Corporation Cycloalkyl substituted imidazoles
US5783597A (en) 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6004960A (en) 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
US6071954A (en) 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6046217A (en) 1997-09-12 2000-04-04 Merck Frosst Canada & Co. 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
FR2769311B1 (fr) 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US6133292A (en) 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US6020347A (en) 1997-11-18 2000-02-01 Merck & Co., Inc. 4-substituted-4-piperidine carboxamide derivatives
FR2771412B1 (fr) 1997-11-26 2000-04-28 Adir Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK1071745T3 (da) 1998-04-24 2004-11-29 Merck & Co Inc Fremgangsmåde til syntetisering af COX-2-inhibitorer
AU3993899A (en) * 1998-05-18 1999-12-06 Merck & Co., Inc. Method for treating or preventing chronic nonbacterial prostatitis and prostatodynia
KR100295206B1 (ko) * 1998-08-22 2001-07-12 서경배 디아릴벤조피란유도체및이를함유하는시클로옥시게네이즈-2저해제조성물
US6277878B1 (en) 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents
US6077869A (en) 1998-10-29 2000-06-20 Ortho-Mcneil Pharmaceutical, Inc. Aryl phenylhydrazides as selective COX-2 inhibitors for treatment of inflammation
US6077868A (en) 1999-07-20 2000-06-20 Wisconsin Alumni Research Foundation Selective inhibition of cyclooxygenase-2
US6083969A (en) 1999-10-20 2000-07-04 Ortho-Mcneil Pharaceutical, Inc. 1,3- and 2,3-diarylcycloalkano and cycloalkeno pyrazoles as selective inhibitors of cyclooxygenase-2 and antiinflammatory agents
CN1294117C (zh) * 2000-03-24 2007-01-10 法马西亚公司 用作一氧化氮合酶抑制剂的脒基化合物及其盐
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares

Also Published As

Publication number Publication date
MEP56908A (en) 2011-05-10
PL205658B1 (pl) 2010-05-31
KR100980685B1 (ko) 2010-09-07
SK12282003A3 (sk) 2005-03-04
OA12498A (en) 2006-05-24
HU229264B1 (en) 2013-10-28
YU85803A (sh) 2006-05-25
TNSN02039A1 (en) 2005-12-23
ATE310516T1 (de) 2005-12-15
UA77173C2 (en) 2006-11-15
CZ20032651A3 (cs) 2004-07-14
NZ528547A (en) 2005-09-30
IS2408B (is) 2008-09-15
EA200301004A1 (ru) 2004-04-29
EP1372645A1 (en) 2004-01-02
HK1244690A1 (zh) 2018-08-17
RS50430B (sr) 2009-12-31
JP2004525949A (ja) 2004-08-26
CN1512882A (zh) 2004-07-14
JP4511792B2 (ja) 2010-07-28
DE60207535D1 (de) 2005-12-29
EP1372645B1 (en) 2005-11-23
NO20034415D0 (no) 2003-10-02
CN107115302A (zh) 2017-09-01
MA27008A1 (fr) 2004-12-20
WO2002080912A1 (en) 2002-10-17
PA8542701A1 (es) 2002-10-28
BR0208652B1 (pt) 2017-10-31
PL368597A1 (en) 2005-04-04
BG66367B1 (bg) 2013-10-31
GEP20063775B (en) 2006-03-27
HRP20030793A2 (en) 2005-10-31
MY137736A (en) 2009-03-31
NO20034415L (no) 2003-12-02
EG24345A (en) 2009-02-11
SI1372645T1 (sl) 2006-06-30
BG108221A (bg) 2010-08-31
AR033688A1 (es) 2004-01-07
CA2442906C (en) 2010-01-12
CN107213121A (zh) 2017-09-29
US7695736B2 (en) 2010-04-13
CA2442906A1 (en) 2002-10-17
HUP0303750A2 (hu) 2004-03-01
NO333381B1 (no) 2013-05-21
HRP20030793B1 (hr) 2013-05-31
IL158209A (en) 2010-05-31
JO2337B1 (en) 2006-06-28
CZ299623B6 (cs) 2008-09-24
ZA200307630B (en) 2004-09-30
GT200200065A (es) 2002-11-15
SK287754B6 (sk) 2011-08-04
IL158209A0 (en) 2004-05-12
US20030078266A1 (en) 2003-04-24
AU2002256031B2 (en) 2006-05-18
HUP0303750A3 (en) 2006-02-28
DK1372645T3 (da) 2006-02-13
BRPI0208652B8 (pt) 2021-05-25
DE60207535T2 (de) 2006-07-20
EA006554B1 (ru) 2006-02-24
AP1776A (en) 2007-08-28
HK1243338A1 (zh) 2018-07-13
PE20021017A1 (es) 2002-11-24
IS6972A (is) 2003-09-30
MXPA03009013A (es) 2004-02-12
KR20030087058A (ko) 2003-11-12
ES2252448T3 (es) 2006-05-16
AP2003002879A0 (en) 2003-12-31
ECSP034789A (es) 2004-07-23
SV2002000969A (es) 2002-12-13
TWI314867B (en) 2009-09-21
TNSN03085A1 (fr) 2005-12-23

Similar Documents

Publication Publication Date Title
BR0208652A (pt) Composição parenteral reconstituìvel contendo um inibidor de cox-2
BRPI0518266A2 (pt) medicamento oral de libertaÇço modificada de pelo menos um princÍpio ativo sob a forma multimicrocapsular
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR037490A1 (es) Composiciones farmaceuticas solidas, proceso para su preparacion, kit para el tratamiento de la obesidad y uso de dichas composiciones en la elaboracion de medicamentos
BR0210350A (pt) Nucleosìdeos 4'-substituìdos
BR0012488A (pt) Composição farmacêutica, métodos para melhorar a taxa de absorção de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para melhorar o inìcio do benefìcio terapêutico de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para inibição de gastroirritação em um mamìfero, e para tratamento de mamìferos necessitando do tratamento proporcionado por um ou mais do que um agente farmaceuticamente ativo, e, processo para preparar uma composição farmacêutica
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
AR012995A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de medicamentos y composiciones farmaceuticas que contienedichos compuestos.
BR0010456A (pt) Uso de xenÈnio para tratar neurointoxicações, preparação inalável e método para produzir uma preparação inalável
BR0108584A (pt) Formulações contendo um fármaco anticolinérgico para o tratamento da broncopneumopatia crÈnica obtrutiva
CO5280073A1 (es) Composiciones
BRPI0714761B8 (pt) formulações compreendendo compostos cíclicos
BR0113539A (pt) Processo para a preparação de composições farmacêuticas para uso com formulações de gelatina macia
BRPI0513417A (pt) composição farmacêutica estável, usos de um poliol, e de uma composição, processo para preparar uma composição farmacêutica, e, método para tratar uma condição responsiva à administração de uma anti-histamina
AR034813A1 (es) Composiciones farmaceuticas y uso de las mismas
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
DK1303278T3 (da) Kombination af et transdermalt terapeutisk system og et oralt og/eller parenteralt præparat indeholdende dopaminagonister til behandling af dopaminerge sygdomme
BR0109747A (pt) Uso de 5-(2-pirazinil)-4-metil-1-2-ditiol-3-tiona (oltipraz) como um medicamento, composição farmacêutica para a prevenção e tratamento da progressão da fibrose hepática, uso de 5-(2-pirazinil)-4-metil-1, 2-ditiol-3-tiona e método para a prevenção e tratamento da progressão da fibrose e da cirrose hepática
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
BR0017329A (pt) Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
BR0317523A (pt) Processo para a preparação de formulações farmacêuticas de combinação utilizando fluidos supercrìticos
BRPI0413374A (pt) composições para liberação de base fraca por um perìodo estendido de tempo
AR002264A1 (es) 6-[triazolil[3(trifluormetil)fenil]metil]-2-quinolinonas y quinolintionas, un procedimiento para su preparacion, una composicion que las comprende, unprocedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento y un intermediario.
AR021491A1 (es) Un compuesto de 6-azauracilo que inhibe a il-5, una composicion que lo comprende, un proceso para preparar dicha composicion, y el uso de dicho compuestopara la manufactura de un medicamento y de un agente de diagnostico
BR0212915A (pt) Uso de uma dose especìfica de sódio de fondaparinux para o tratamento de acs

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/04/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 02/04/2022